Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Potenza Therapeutics

- PMLiVE

Astellas forms new US corporate affairs unit

Jeff Winton will lead the department, which adds two newemployees

- PMLiVE

Novartis aims to lead immuno-oncology category

Firm believes its immuno-oncology pipeline will help it overtake leader Roche

ASCO 2015: What you missed in Chicago

Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations...

Blue Latitude Health

- PMLiVE

Astellas’ Xtandi cancer drug rejected by NICE

England’s HTA questions the treatment’s efficacy and cost

Pharma deals in May 2015

The number of corporate acquisitions drops, finds Medius Deal Watch

- PMLiVE

AZ pushes immuno-oncology duo into phase III

MEDI4736 and tremelimumab achieved disease control in 48% of NSCLC patients

- PMLiVE

Ipsen acquires OctreoPharm to boost its oncology presence

Will aid the development of its approach to neuroendrocrine tumours

- PMLiVE

2015 set to be a transitional year for Merck KGaA’s health unit

Weak pharma sales reported by the firm today

- PMLiVE

Endo buys Par for $8bn as M&A mania marches on

Acquisitionwill make Endo the fifth largest generics company in the US

Pharma deals in April 2015

The love affair with oncology continues, finds Medius Deal Watch

Medius Deal Watch table for April 2015

The top major pharma mergers, acquisitions and collaborations during the month continued pharma's love affair with oncology

Pharma deals in March 2015

AbbVie's Pharmacyclics mega-merger dominated the month, finds Medius Deal Watch

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links